top of page

Decoding CNS Drug Discovery with SynFire  iP

®

blue green wave lines.png

NeuCyte is an innovative biotechnology company focused on CNS drug discovery.

Based on its proprietary SynFire® technology for generating human iPSC-derived neurons, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. The team is actively pursuing drug discovery programs on Alzheimer's disease, ALS, Epilepsy, Fragile X Syndrome and more.

1.png

Our Unique Approach

The high attrition rate of novel CNS drugs during clinical development has been a major challenge to the pharmaceutical industry. This is largely attributed to the lack of biologically relevant models to study functional links between target and phenotype.

NeuCyte’s mission is to accelerate and optimize CNS drug discovery by developing more predictive assays and platforms for phenotypic screening.

blue green wave lines.png

SynFire   Technology

®

Based on the advantageous SynFire technology for generating human induced pluripotent stem cell (iPSC)-derived induced neuronal cells (iNs), NeuCyte has developed a proprietary in vitro human neural platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment.

 

Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modeling neurological and neurodegenerative disorders.

blue green wave lines.png
Web_Movie_B4_3.gif

Drug Discovery

With our proprietary technology platform and exciting collaborations, NeuCyte is actively pursuing drug discovery programs for several genetically defined neurological diseases.

blue green wave lines.png

Latest News

sfn.png

Booth 1802

Adam Caar

Society for Neuroscience

Washington, DC

November 11-15, 2023.

Poster 196: Developing platforms with AD GWAS iPSC-derived Microglia for High-Throughput Drug Screening

Booth: 1802

nih.png

Mountain View, CA, USA, August 14, 2023. NeuCyte, Inc., an innovative biotechnology company focused on developing novel treatments for neurological and neurodegenerative disorders, announced that the company has been awarded a National Institute of Health Small Business Technology Transfer (STTR) grant in collaboration with University of California at San Francisco (UCSF) and Acoustic Bio to develop a microfluidics-based high-throughput drug-screening platform for Alzheimer Disease/Alzheimer Disease-related Dementias (AD/ADRD).

ISSCR.jpeg

Adam Caar

International Society of Stem Cell Research Annual Meeting

Boston, Massachusetts

June 14-17, 2023.

Poster 487: Miniaturized Isogenic iPSC-Derived 3D NeuroImmune Assembloids for High-Throughput Drug Screening

Poster 707: Development of iPSC-Derived Pre-Clinical Drug Screening Assays for KIF1A Associated Neurological Disorder (KAND) 

NeuCyte and KIF1A.ORG Enter Collaboration Agreement

kif1a.png

Adam Caar

San Carlos, California, USA, August 17, 2021.

NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with KIF1A.ORG.

NeuCyte and Mount Sinai Enter Collaboration Agreement

mount sinai _edited.png

Developer

San Carlos, California, USA, January 19, 2021.

NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai.

Looking for an exciting and rewarding career opportunity?

NeuCyte-Logo_original_blue[37082].png

Adam Caar

Take on an exciting journey to accelerate and optimize drug discovery with fellow neuroscientists

Leave your mark, Improve lives

Developer

blue green wave lines.png

Let's stay connected. Subscribe to our newsletter!

Thanks for subscribing!

bottom of page